US Patent 6,469,035 (Extended-Release Nicotinic Acid Flushing Reduction + Statin Co-Administration): Claim Scope and Patent Landscape
US Drug Patent 6,469,035 is directed to methods that (i) reduce or prevent the flushing reaction provoked by extended-release (ER) nicotinic acid dosed once daily in the evening or before/at bedtime, and (ii) do so via oral pretreatment with a flush-inhibiting agent that targets PGD2 (prostaglandin PGD2)–mediated flushing, while maintaining lipid alteration without treatment-limiting hepatotoxicity, and without glucose and/or uric acid elevations; dependent claims broaden into adding an HMG-CoA reductase inhibitor (statin) and into specific dosage forms, dosages, and excipients/coatings.
What does claim 1 actually cover?
Claim 1 is the keystone method claim. Its scope is constrained by a tight combination of: (a) the nicotinic acid formulation and dosing time, (b) the purpose (reduce flushing capacity), (c) pretreatment with a specific mechanistic class, and (d) safety/biomarker limits.
Claim 1 elements (hard constraints)
A. Target product and administration schedule
- Extended-release nicotinic acid administered orally
- Dose is “effective lipid-altering amount”
- Given as a single dose once a day
- Dosed during the evening hours or before or at bedtime
B. Pretreatment step
- Orally pretreat the individual with an effective flush inhibiting amount of a flush inhibiting agent
- Pretreatment period is “for a sufficient period of time prior to initiating” ER nicotinic acid
- The goal is to inhibit or reduce prostaglandin PGD2 induced by ER nicotinic acid
C. Outcome and tolerability limits
- The method produces “reduced or prevented” flushing capacity
- The administration is in a way that is “without causing treatment-limiting hepatotoxicity and elevations in glucose and/or uric acid levels”
Practical interpretation for scope design
The claim is not just “reduce flushing.” It requires:
- ER nicotinic acid given once daily in the evening/bedtime window
- Oral pretreatment that suppresses PGD2-mediated flushing
- The regimen must avoid two safety/biomarker failure modes: hepatotoxicity and glucose and/or uric acid elevations
That combination makes the protected method narrower than general “aspirin reduces niacin flushing” art.
(Claim text source: US 6,469,035 claims as provided.)
How do dependent claims narrow or expand the protected method?
Are NSAIDs the main flush-inhibiting agents?
Yes. Claims 6-8 anchor the flush inhibiting agent class.
- Claim 6: flush inhibiting agent is an NSAID
- Claim 7: NSAID is selected from a specified list (indomethacin, sulindac, etodolac, aspirin, salicylate salts, ibuprofen, fluribprofen, fenoprophen, suprofen, benoxaprofen, ketoprofen, carprofen, naproxen, sodium naproxen, aclofenac, diclofenac, fenclofenac, tolmetin, zomepirac, meclofenamate, mefanamic acid, oxyphenbutazone, phenylbutazone, piroxicam, etc.)
- Claim 8: flush inhibiting agent is aspirin
Scope impact: With Claim 6-7, the patent covers NSAID-based pretreatment across a broad NSAID genus. Claim 8 then isolates aspirin as an emphasized embodiment.
How is aspirin dosing defined?
Claims 9-16 define aspirin administration cadence and daily dose bands.
- Claim 9: aspirin pretreatment given in one to four doses per day
- Claim 10: aspirin dose band about 80 mg to about 1000 mg daily
- Claims 11-16: additional aspirin variants
- Claim 13: aspirin can be one or two doses per day
- Claim 14: 80 mg to 1000 mg daily
- Claim 15: 80 mg to 650 mg daily
- Claim 16: 80 mg to 325 mg daily
Scope impact: The claim set supports both broad aspirin daily dosing ranges and narrower preferred windows, improving enforcement flexibility against infringing regimens that choose mid-range doses.
Does the patent require pretreatment only, or also co-therapy with statins?
Claim 2 expands claim 1 by adding an HMG-CoA reductase inhibitor (statin) requirement.
-
Claim 2: method includes further step of orally administering an HMG-CoA reductase inhibitor
- lipid-altering amount
- without treatment-limiting myopathy and rhabdomyolysis
-
Claim 3: statin administration is concomitant with ER nicotinic acid oral administration
-
Claim 4: statin can be extended-release or immediate-release
-
Claim 5: statin is selected from atorvastatin, cerivastatin, flavastatin, lovastatin, pravastatin, simvastatin
Scope impact: Claim 2 shifts the protected method from flush management alone to flush management plus lipid modification using a statin while controlling statin-specific risks (myopathy/rhabdomyolysis).
Which nicotinic acid species are within the claim?
Claim 17-18 specify nicotinic acid “compound” embodiments.
- Claim 17: further step of orally administering a nicotinic acid compound in an effective lipid-altering amount
- Claim 18: ER nicotinic acid compound selected from an enumerated list including:
- nicotinyl alcohol tartrate
- d-glucitol hexanicotinate
- aluminum nicotinate
- niceritrol
- d, 1-alpha-tocopheryl nicotinate
- 6-OH-nicotinic acid
- nicotinaria acid
- nicotinamide / nicotinamide-N-oxide (and related derivatives listed)
- NAD, and multiple N-alkylated nicotinamide / pyridone carboxamide derivatives
- lower alcohol esters of nicotinic acid
- plus other named derivatives in the list
Scope impact: The patent is not limited to free nicotinic acid. It reaches a broader class of niacin-related nicotinate forms used as ER prodrugs/esters or derivatives.
How does claim 21 change the landscape: a fixed-dose co-administration format?
Claim 21 is a broader method that also introduces a single oral solid dosage form concept, where ER nicotinic acid is combined with an immediate-release statin and delivered as one dose.
Claim 21 key additions vs claim 1
A. Mechanistic pretreatment remains
- Orally pretreat with flush inhibiting agent to inhibit/reduce PGD2 induced by ER nicotinic acid
B. Delivery structure changes
- Orally administer an oral solid dosage form composed of:
- ER nicotinic acid in effective lipid-altering amount
- and an immediate release HMG-CoA reductase inhibitor in effective lipid-altering amount
- Delivered as a single dose once a day in the evening/bedtime window
C. Outcome
- Reduced/prevented flushing capacity
- Serum lipid levels altered
- Also tied to avoiding treatment-limiting hepatotoxicity, myopathy, rhabdomyolysis, and glucose/uric acid elevations
Scope impact: Claim 21 is where the patent becomes more “product-like” in structure (single oral solid dosage form), which is often where generic and reformulation strategies are most likely to collide.
(Claims 22-30 then define dosage form/tablet architecture and dose ranges.)
What are the product-dose and formulation constraints in claims 22-30?
Solid dosage form requirements
- Claim 22: oral solid dosage form is a tablet
- Claim 23: ER nicotinic acid is coated with the immediate release statin
- Claim 24: oral solid dosage form is a tablet (reinforcing form type)
- Claim 25: tablet architecture:
- inner core contains ER nicotinic acid
- coating layer contains immediate release HMG-CoA reductase inhibitor
- inner core is coated with coating layer
Amount ranges
Claims 26-30 define the dosing ranges inside the tablet:
- Claim 26/27/28/29/30 (same numeric band):
- ER nicotinic acid: about 250 mg to about 1,000 mg
- immediate release statin: about 0.05 mg to about 80 mg
Scope impact: These numeric ranges can be used as enforcement thresholds if an accused product changes either ER niacin dose or statin dose outside the bands.
How broad is claim coverage across statin classes?
Claim 2-5 include multiple statins, and claim 21 includes “immediate release HMG-CoA reductase inhibitor” as part of the solid dosage form. Statin genus coverage is therefore not limited to one active.
Statin list in claim 5
- atorvastatin
- cerivastatin
- flavastatin
- lovastatin
- pravastatin
- simvastatin
Statin formulation options
- Claim 4 allows ER or IR statin generally in claim 2
- Claim 21 specifies immediate release HMG-CoA reductase inhibitor in the dosage form and further defines coating arrangement (claims 23-25)
Does the patent cover other lipid agents besides statins?
Yes. Claims 19-20 introduce bile acid sequestrants as further steps in the method (as dependent claims under the claim 17/11 umbrella).
- Claim 19: further step of orally administering cholestyramine in effective lipid-altering amount
- Claim 20: further step of orally administering colestipol in effective lipid-altering amount
Scope impact: This expands potential claim construction for combination regimens. However, the independent claim core (claim 1) is flush reduction via PGD2 inhibition with an NSAID/aspirin strategy and ER niacin dosing schedule.
Claim map (condensed)
| Claim |
Core objective |
“Must-have” elements (high-level) |
| 1 |
Reduce/avoid ER niacin flushing capacity |
ER nicotinic acid once daily evening/bedtime + oral pretreatment with flush inhibitor that inhibits/reduces PGD2 + no treatment-limiting hepatotoxicity and no glucose/uric acid elevations |
| 2 |
Add statin lipid alteration while avoiding statin muscle risks |
claim 1 + oral HMG-CoA reductase inhibitor without myopathy/rhabdo |
| 3 |
Timing of statin |
claim 2 with statin concomitant with ER niacin |
| 4 |
Statin release form |
claim 2 with ER or IR statin allowed |
| 5 |
Specific statins |
claim 2 with statin selected from listed group |
| 6-8 |
Flush inhibitor class and aspirin |
NSAID (6-7), then aspirin (8) |
| 9-16 |
Aspirin dosing |
one to four doses/day; daily band ranges down to 80-325 mg/day |
| 17-18 |
Niacin compound species |
includes enumerated ER nicotinic acid derivatives/forms |
| 19-20 |
Alternative lipid adjuncts |
cholestyramine or colestipol |
| 21 |
Fixed-dose structure |
oral solid dosage form containing ER niacin + immediate-release statin + oral solid once daily evening/bedtime + PGD2-inhibiting pretreatment + safety limits |
| 22-25 |
Tablet architecture |
tablet; ER niacin coated with IR statin; inner core/coating layers |
| 26-30 |
Dose ranges |
ER niacin 250-1000 mg; IR statin 0.05-80 mg |
(All claim text is from the claims you provided for US 6,469,035.)
Patent landscape analysis (enforcement and design-around posture)
How to read this patent in the niacin-flush + statin combo space
US 6,469,035 creates protection at two levels:
- Method level (claims 1 and 2): oral pretreatment that targets PGD2 plus controlled dosing schedule and safety outcomes.
- Product-architecture level (claims 21-30): fixed tablet structure where ER niacin is coated with an immediate release statin, with defined dose bands.
That structure matters because many competing approaches fall into one of three buckets:
- “Flush management without PGD2 targeting” (likely outside claim 1’s mechanistic limitation)
- “PGD2/NSAID pretreatment without the evening/bedtime once-daily ER regimen” (likely outside claim 1 schedule limitation)
- “ER niacin + statin combination without the fixed-dose tablet/coating structure and immediate-release statin coating feature” (likely outside claim 21-25)
High-risk technical design points for challengers/infringers
1) Mechanism peg: PGD2 inhibition/reduction
Claim 1 requires pretreatment that inhibits or reduces PGD2 induced by ER nicotinic acid. If an accused regimen relies on a different biochemical mediator, that can create a scope separation.
2) Release form and timing
- ER nicotinic acid must be administered once daily during evening/bedtime window
- Claim 21 then narrows the statin portion to immediate release in the solid dosage form and ties it to the coating design
3) Safety constraints are claim limitations
The claim text conditions the method so that it is done “without causing”:
- treatment-limiting hepatotoxicity (claim 1 and claim 21)
- elevations in glucose and/or uric acid (claim 1 and claim 21)
- treatment-limiting myopathy and rhabdomyolysis when statins are used (claim 2 and claim 21)
In litigation terms, these are not merely background risks; they define the regimen’s acceptable clinical outcome.
4) Dose bands in claims 26-30
The tablet dose ranges provide a numerical boundary:
- ER niacin: 250-1000 mg
- immediate-release statin: 0.05-80 mg
If a product deliberately lands outside those bands, claims 26-30 may be harder to apply even if the overall concept matches.
Likely relevance to generic or reformulation strategies
A generic attempting to replicate the combination effect without crossing claim 21-25 constraints could pursue:
- alternative tablet architecture (avoid inner core coated with IR statin coating layer)
- alternative statin release form (avoid “immediate release” as specified for claim 21 coating)
- avoid the defined ER niacin dose band
A competitor focusing only on aspirin pre-treatment (NSAID approach) without statin co-formulation would still face claim 1 depending on whether the PGD2 mechanism and schedule/time window are met.
Claim scope summary for investment/R&D decisions
US 6,469,035 is best understood as a protection bundle that targets the niacin flushing problem through oral NSAID pretreatment designed to reduce PGD2, while also building enforceable coverage for a niacin-statin fixed-dose tablet where ER niacin is coated with immediate-release statin and administered once daily in an evening/bedtime window.
Key Takeaways
- Claim 1 protects a specific clinical regimen: ER nicotinic acid once daily at evening/bedtime plus oral pretreatment with a PGD2-inhibiting flush inhibitor, while avoiding hepatotoxicity and glucose/uric acid elevations.
- Claims 6-8 and 9-16 anchor the flush inhibitor to NSAIDs, with aspirin emphasized through dose cadence and daily dose ranges (about 80 to 1000 mg/day, with narrower bands down to 80-325 mg/day).
- Claims 2-5 add an HMG-CoA reductase inhibitor lipid strategy with explicit avoidance of myopathy/rhabdomyolysis, naming atorvastatin, cerivastatin, flavastatin, lovastatin, pravastatin, simvastatin.
- Claims 21-25 shift from a regimen claim to a dosage-form architecture claim: a tablet with ER niacin as an inner core coated with an immediate-release statin coating layer.
- Claims 26-30 provide numeric guardrails: ER nicotinic acid 250-1000 mg and IR statin 0.05-80 mg inside the tablet.
FAQs
1) Does US 6,469,035 require PGD2 involvement?
Yes. Claim 1 requires pretreatment that inhibits or reduces prostanglandin PGD2 induced by ER nicotinic acid.
2) Is aspirin the only flush inhibitor covered?
No. NSAIDs are covered in claims 6-7, and aspirin is singled out in claims 8-16 with explicit dosing bands.
3) Can the statin be extended-release under the broader claims?
Under claim 2-4, yes. Claim 21-25 specifically require an immediate release statin in the tablet coating arrangement.
4) What part of the patent is most likely to constrain fixed-dose combo products?
Claims 21-25 (tablet architecture and coating with immediate-release statin) and claims 26-30 (dose ranges).
5) What are the key clinical “failure modes” the claims try to avoid?
The claims explicitly avoid: treatment-limiting hepatotoxicity, glucose and/or uric acid elevations, and (when statins are present) treatment-limiting myopathy and rhabdomyolysis.
References
- US Patent 6,469,035 (claims as provided by user).
